Valuation: Lakefront Biotherapeutics NV

Market Cap 1.55B 1.78B 1.44B 1.33B 2.5B 170B 2.54B 17.03B 6.67B 84.62B 6.69B 6.54B 279B P/E 2026 *
-11x
P/E 2027 * -8.31x
Enterprise Value -436M -502M -407M -374M -705M -47.82B -717M -4.8B -1.88B -23.85B -1.88B -1.84B -78.65B EV / Sales 2026 *
-30.6x
EV / Sales 2027 * -9.68x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day-1.19%
1 week-6.07%
Current month-2.77%
1 month-12.12%
3 months-4.13%
6 months-20.17%
Current year-17.14%
1 week 23
Extreme 23
25.04
1 month 23
Extreme 23
27.12
Current year 22.62
Extreme 22.62
30.72
1 year 22.62
Extreme 22.62
32.74
3 years 20
Extreme 20
39
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Director

137 0.0002%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-6.07%-19.50%-41.25% 1.78B
-0.11%-0.11%-1.06%+13.51% 48.22B
+1.62%+1.27%+400.81%+496.60% 38.79B
-1.73%-5.43%+25.72%+5.91% 38.41B
+0.94%-3.87%+4.39%+57.05% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.10%-0.13%+31.87%+120.38% 16B
-1.02%-4.44% - - 16.05B
+1.74%+0.58%+3.58%+16.97% 13.53B
-1.52%-13.30%-5.18%-38.32% 12.22B
Average -0.37%-1.13%+50.26%+74.34% 24.91B
Weighted average by Cap. -0.24%+0.11%+74.83%+106.68%

Financials

2026 *2027 *
Net sales 14.24M 16.39M 13.3M 12.21M 23.01M 1.56B 23.41M 157M 61.4M 779M 61.55M 60.18M 2.57B 46.09M 53.03M 43.03M 39.5M 74.48M 5.05B 75.78M 507M 199M 2.52B 199M 195M 8.31B
Net income -811M -933M -757M -695M -1.31B -88.91B -1.33B -8.92B -3.5B -44.34B -3.5B -3.43B -146B -238M -274M -222M -204M -384M -26.08B -391M -2.62B -1.03B -13.01B -1.03B -1B -42.9B
Net Debt -1.98B -2.28B -1.85B -1.7B -3.21B -218B -3.26B -21.83B -8.55B -108B -8.57B -8.38B -358B -1.99B -2.29B -1.86B -1.71B -3.22B -219B -3.28B -21.95B -8.6B -109B -8.62B -8.43B -360B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
26-08-04 23.18 -1.28% 69,856
26-08-03 €23.48 -1.59% 93,899
26-07-31 €23.86 -1.00% 94,021
26-07-30 €24.10 -1.79% 87,672
26-07-29 €24.54 -0.65% 61,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
23.48EUR
Average target price
30.28EUR
Spread / Average Target
+28.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock